Your browser doesn't support javascript.
loading
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo, Marta; Cruz, Cristina; Llop-Guevara, Alba; Gutiérrez-Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris-Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles-Fernández, Alejandro; Villacampa, Guillermo; Viaplana, Cristina; Gómez, Patricia; Vidal, Maria; Peg, Vicente; Serres-Créixams, Xavier; Dellaire, Graham; Simard, Jacques; Nuciforo, Paolo; Rubio, Isabel T; Dienstmann, Rodrigo; Barrett, J Carl; Caldas, Carlos; Baselga, José; Saura, Cristina; Cortés, Javier; Déas, Olivier; Jonkers, Jos; Masson, Jean-Yves; Cairo, Stefano; Judde, Jean-Gabriel; O'Connor, Mark J; Díez, Orland; Balmaña, Judith; Serra, Violeta.
Afiliación
  • Castroviejo-Bermejo M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Cruz C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Llop-Guevara A; High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Gutiérrez-Enríquez S; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Ducy M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Ibrahim YH; Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Gris-Oliver A; Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada.
  • Pellegrino B; Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada.
  • Bruna A; CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada.
  • Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bonache S; Department of Medical Oncology, University Hospital of Parma, Parma, Italy.
  • Moles-Fernández A; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Villacampa G; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Viaplana C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Gómez P; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Vidal M; Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Peg V; Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Serres-Créixams X; Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Dellaire G; Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Simard J; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Nuciforo P; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rubio IT; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Dienstmann R; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Barrett JC; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Caldas C; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Baselga J; Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Saura C; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
  • Cortés J; CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada.
  • Déas O; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Jonkers J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Masson JY; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Cairo S; Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Judde JG; Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • O'Connor MJ; AstraZeneca, Waltham, MA, USA.
  • Díez O; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Balmaña J; Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK.
  • Serra V; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
EMBO Mol Med ; 10(12)2018 12.
Article en En | MEDLINE | ID: mdl-30377213
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Recombinasa Rad51 / Xenoinjertos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2018 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Recombinasa Rad51 / Xenoinjertos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2018 Tipo del documento: Article País de afiliación: España